EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antimicrobial Nanoparticles Against Superbugs: Mechanistic Insights, Biomedical Applications, and Translational Frontiers

Ayman Elbehiry iD, Adil Abalkhail iD

Pharmaceuticals · 13.08.2025 · 18 (8) · 1195

DOI: 10.3390/ph18081195 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 13.08.2025. Verfasst von Ayman Elbehiry und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, College of Applied Medical Sciences, Qassim University, P.O. Box 6666, Buraydah 51452, Saudi Arabia. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 208 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The accelerating threat of antimicrobial resistance (AMR) demands transformative strategies that go beyond conventional antibiotic therapies. Nanoparticles (NPs) have emerged as versatile antimicrobial agents, offering a combination of physical, chemical, and immunological mechanisms to combat multidrug-resistant (MDR) pathogens. Their small size, surface tunability, and ability to disrupt microbial membranes, generate reactive oxygen species (ROS), and deliver antibiotics directly to infection sites position them as powerful tools for infection control. This narrative review explores the major classes, mechanisms of action, and biomedical applications of antimicrobial NPs—including their roles in wound healing, implant coatings, targeted drug delivery, inhalation-based therapies, and the treatment of intracellular infections. We also highlight the current landscape of clinical trials and evolving regulatory frameworks that govern the translation of these technologies into clinical practice. A distinctive feature of this review is its focus on the interplay between NPs and the human microbiota—an emerging frontier with significant implications for therapeutic efficacy and safety. Addressing this bidirectional interaction is essential for developing microbiota-informed, safe-by-design nanomedicines. Despite promising advances, challenges such as scalability, regulatory standardization, and long-term biosafety remain. With interdisciplinary collaboration and continued innovation, antimicrobial NPs could reshape the future of infectious disease treatment and help curb the growing tide of AMR.

Schlagwörter

Stichwörter der Autor:innen

antimicrobial nanoparticlesbiofilm-associated infectionsmultidrug-resistant infectionspublic healthtargeted drug deliverytranslational nanomedicine

Autor:innen und Institutionen

  • Department of Public Health, College of Applied Medical Sciences, Qassim University, P.O. Box 6666, Buraydah 51452, Saudi Arabia.

ORCID-Profile: Ayman Elbehiry, Adil Abalkhail

Zitieren

APA

Elbehiry, A., & Abalkhail, A. (2025). Antimicrobial Nanoparticles Against Superbugs: Mechanistic Insights, Biomedical Applications, and Translational Frontiers. Pharmaceuticals, 18(8), 1195. https://doi.org/10.3390/ph18081195

Vancouver

Elbehiry A, Abalkhail A. Antimicrobial Nanoparticles Against Superbugs: Mechanistic Insights, Biomedical Applications, and Translational Frontiers. Pharmaceuticals. 2025;18(8):1195. doi:10.3390/ph18081195

BibTeX
@article{Elbehiry2025,
  author = {Elbehiry, Ayman and Abalkhail, Adil},
  title = {Antimicrobial Nanoparticles Against Superbugs: Mechanistic Insights, Biomedical Applications, and Translational Frontiers},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {8},
  pages = {1195},
  doi = {10.3390/ph18081195}
}
Kostenlos starten →